By a News Reporter-Staff News Editor at Pharma Business Week Imprimis Pharmaceuticals, Inc. announced that Gus Bassani, Pharm. Imprimis Pharmaceuticals is dedicated to improving patient health and quality of life by leveraging a patented topical drug delivery platform that enables highly targeted site specific treatment. He has worked in multiple
Radius Health, Inc. and 3 M Drug Delivery Systems announced an exclusive partnership agreement for development and commercialization of BA058-transdermal. BA058-TD is a short-wear time patch based on 3 M's patented Microstructured Transdermal System technology. Our study data for BA058-TD showed that a five-minute wear time of the patch delivers pe
A report, 'Single-use disposable dry powder inhalers for pulmonary drug delivery,' is newly published data in Expert Opinion On Drug Delivery. "Thereby, single-use disposable dry powder inhalers may be considered an economically and therapeutically valuable option for both local and systemic administration of drugs to treat a variety of different d
Dec 28, 2011 IntelGenx Corp., a drug delivery company, has announced that the company has entered into a co-development and commercialization agreement with Par Pharmaceutical, Inc., a manufacturer of generic drugs, for a new product utilizing one of IntelGenx' oral drug delivery platforms.
Research and Markets has announced the addition of GlobalData's new report "Drug Delivery Devices Market Outlook in Japan to 2016 - Inhalation Systems, Infusion Systems and Others" to their offering. This medical device report, Drug Delivery Devices Market Outlook in Japan to 2016 - Inhalation Systems, Infusion Systems and Others provides key marke
Dec 24, 2012 Antares Pharma, Inc., a pharma company that focuses on self-injection pharmaceutical products, has announced the submission of a new drug application, or NDA, to the FDA for OTREXUP, a combination product for the delivery of methotrexate, or MTX, using Medi-Jet technology. The NDA submission, subject to acceptance and approval by the
Dec 24, 2012 Atlantic Pharmaceuticals, Inc., a specialty pharmaceutical company, has received new patents from US Patent and Trademark Office, or USPTO, relating to its tamper resistant SMART/Script drug delivery platform. US Patent Nos. 8,187,636 and 8,349,362 contain claims that cover the company's tamper resistant platform which are designed t
SCOLR Pharma, Inc. today announced that it has received and shipped initial retail orders for its extended-release nutritional products based on the Company's proprietary CDT oral drug delivery platform.
The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our selected financial data and our financial statements and the accompanying notes included in this annual report. Overview. Positron Corporation is a molecular imaging company focused on Nuclear Cardiology.
Alexza Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration approved ADASUVE^ Inhalation Powder 10 mg for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults. ADASUVE combines Alexza's proprietary Staccato^ delivery system with the antipsychotic drug, loxapine.
Research and Markets has announced the addition of Jain PharmaBiotech's new report "Transdermal Drug Delivery- Technologies, Markets, and Companies" to their offering.
Atlantic Pharmaceuticals, Inc., a specialty pharmaceutical company, today announced that new patents have been issued by the U.S. Patent and Trademark Office relating to its tamper-resistant SMART/Script? drug delivery platform. "We believe SMART/Script? is a unique technology that may have a significant effect on prescription drug abuse and m
By a News Reporter-Staff News Editor at Gene Therapy Weekly Bio-Path Holdings, Inc.,, a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, announced it is initiating development of its lead cancer drug BP-100-1.01 to treat triple negative breast cancer and inflammatory breast cancer, two cancers...
WARREN, N.J., Dec. 20, 2012 MonoSol Rx, the developer of PharmFilm drug delivery technology, today announced it has acquired U.S. A. Mark Schobel, Co-President and Chief Executive Officer of MonoSol Rx, stated, "The addition of this patent to our IP portfolio reinforces MonoSol Rx as a leader and innovator in pharmaceutical film technology, an
Radius Health, Inc. and 3 M Drug Delivery Systems are pleased to announce an exclusive partnership agreement for development and commercialization of BA058-transdermal. We are excited that 3 M Drug Delivery Systems, which has long demonstrated a commitment to quality, safety and innovation, is partnering with us to bring a novel approach of drug
By a News Reporter-Staff News Editor at Biotech Week Research findings on Drugs and Therapies are discussed in a new report. The news reporters obtained a quote from the research from the University of California, "The ex vivo heart was imaged with confocal microscopy and the in vivo heart with positron emission tomography in sham-treated mice an
EyeGate Pharma, a privately held specialty pharmaceutical company developing a non-invasive ocular drug delivery platform and ocular therapeutics, announces today that they have enrolled the last patient in the pivotal Phase III study of EGP-437 in patients with anterior uveitis. A previous Phase I/II study demonstrated that a single EGP-437 treatm
Imprimis Pharmaceuticals is dedicated to improving patient health and quality of life by leveraging a patented topical drug delivery platform that enables highly targeted site specific treatment. Its lead drug candidate, Impracor, utilizes the company's innovative Accudel? cream formulation to deliver ketoprofen, a non-steroidal anti-inflammatory
Dec 18, 2012 Photocure ASA, a specialty pharmaceutical company focused on photodynamic technologies in dermatology and cancer, has announced the initial three month results of the Phase IIb study of Cevira in patients with human papilloma virus, or HPV, related disease of the cervix. Cevira, an integrated drug-delivery device, demonstrated signif
Dec 18, 2012 Skinvisible Pharmaceuticals, Inc., an R&D pharmaceutical company, has received US patent 8,318,818 for topical drug delivery technology, Invisicare from USPTO, or United States Patent and Trademark Office. Terry Howlett, president and CEO, said: "The granting of this latest patent is fundamental to our intellectual property portfolio
RDATE:17122010. Dublin - Research and Markets has announced the addition of GlobalData 's new report "Asia-Pacific Drug Delivery Devices Market Outlook to 2016" to their offering. The new report, Asia-Pacific Drug Delivery Devices Market Outlook to 2016 provides key market data on the Asia-Pacific Drug Delivery Devices market Japan, China, Australi
RDATE:16122010. Dublin - Research and Markets. has announced the addition of GlobalData 's new report "North America Drug Delivery Devices Market Outlook to 2016" to their offering. North America Drug Delivery Devices Market Outlook to 2016. Summary.
Research and Markets has announced the addition of GlobalData 's new report "North America Drug Delivery Devices Market Outlook to 2016" to their offering. North America Drug Delivery Devices Market Outlook to 2016. Summary. Our new report, North America Drug Delivery Devices Market Outlook to 2016 provides key market data on the North America Drug
WARREN, N.J. and PORTAGE, Ind., Dec. 14, 2010 MonoSol Rx, the developers of PharmFilm technology and a drug delivery company specializing in proprietary pharmaceutical film products, announced today it secured favorable terms to refinance the company's debt with White Oak Global Advisors, LLC.
Dec 13, 2012 InSite Vision Incorporated has completed patient enrollment in first Phase III clinical trial of BromSite for the reduction of pain and inflammation after cataract surgery. BromSite combines a low dose of the non-steroidal anti-inflammatory drug bromfenac with InSite Vision's DuraSite drug delivery technology. Begun in August, our te
